Martindale Pharma’s oral clobazam approved in seven European countries

Martindale Pharma has been granted regulatory approval for its clobazam oral suspension product in seven European countries.

The epilepsy therapy has been approved for sale under the brand name Epaclob in France, Ireland, Germany and Italy, while in Denmark, Spain and Iceland it will be sold under the name Silocalm.

This new product is based on Tapclob, the world's first oral liquid suspension version of clobazam to receive regulatory approval, which has been sold in the UK since May 2013.

It is intended for use as an adjunctive therapy for epilepsy and is particularly suitable for children and young adults. Two different strengths will be supplied in packs containing dosing syringes and dosage cups, facilitating accurate dosing to aid treatment adherence.

Michael Harris, chief executive officer of Martindale Pharma, said: "This formulation not only allows for better ease of use, especially for paediatrics, but will allow both prescribers and patients access to a much-needed safe and cost-effective licensed oral liquid formulation when required."

The UK-based firm provides medicines to customers in more than 50 countries around the world.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.